Navigation Links
Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports
Date:11/1/2010

ctor contributing to the increase in growth over the forecast period is the increase in disease incidence and the launch of new first-in-class drugs. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as clopidogrel (Plavix) and ticlopidine (Ticlid). Blood thinners such as pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. Like most cardiovascular complications, aspirin is used as a complementary drug in combination with the above mentioned drugs.

Scope

The report provides information on the key drivers and challenges of the PAD market. Its scope includes: - Annualized global PAD market revenues data from 2001 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of gene therapy, stem cell therapy, platelet aggregation inhibitor, Hydroxymethylglutaryl-CoA reductase inhibitor, monoclonal antibody, micro RNA, protein kinase modulator, Y2 agonist, and PPAR (Peroxisome Proliferator Activated Receptor) agonist. - Analysis of the current and future competition in the global PAD market. Key market players covered are Sanofi Aventis, Indigo pharmaceuticals, BioMarin Pharmaceutical, and AnGes MG Inc. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PAD therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strateg
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peripheral Artery Disease (PAD) Patent Granted to Dimera
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
4. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
5. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
6. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
8. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
9. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
10. 550 People Across Europe Will Die Today From a Preventable Lung Disease
11. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies ... lethal strains of E. Coli preceded the current E. Coli ... in laboratories in Germany and elsewhere since 1995, and genome ... subsequences of the genome of an infectious agent that have ...
... June 20, 2011 Genetic Technologies Limited (ASX: GTG; ... division, Phenogen Sciences Inc., has launched the new BREVAGen™ ... Phenogen Sciences will target its promotion campaign ...  The company has deployed its sales force to service ...
... , Kuros Biosurgery AG, a ... and bioactive-biomaterial,combination products for trauma, wound and spinal ... by the European Patent Office. This now allowed ... portfolio of applications,and patents designed to protect Kuros’ ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... may help prevent potentially dangerous bacteria like Staphylococcus ... animals, scientists heard today (Monday 8 September 2008) ... being held this week at Trinity College, Dublin. ... protect them against antibiotics and the body,s natural ...
... Researchers in Switzerland have developed a new ... in microfluidic systems, these "Pyrex"-like nanoparticles are ... and harsh chemical environments than currently used ... Their introduction could extend the range of ...
... INCF Congress of Neuroinformatics will convene September 7-9 ... The emerging neuroinformatics field combines neuroscience and informatics ... understanding the structure and function of the brain. ... disorders and diseases. With a broad international outreach, ...
Cached Biology News:Milk may help bacteria survive against low levels of antibiotics 2INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2